Crossmark

RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting m6A methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype

Crossref DOI link: https://doi.org/10.1186/s41065-025-00534-0

Published Online: 2025-08-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fu, Jinkun

Wei, Chao

Chen, Yijian

He, Xiaoming

Zhang, Kun
License Information

Text and Data Mining valid from 2025-08-19

Version of Record valid from 2025-08-19
More Information

Article History

Received: 20 June 2025

Accepted: 7 August 2025

First Online: 19 August 2025

Declarations

:

: The present study was approved by the ethical review committee of Xianyang Hospital of Yan'an University with approval No.20240128. Written informed consent was obtained from all enrolled patients. Patients agree to participate in this work

: The authors declare no competing interests.

: The authors declare that they have no financial or non-financial conflicts of interest.

Document is current

Any future updates will be listed below